Eywa Pharma
Eywa Pharma is a Singapore-headquartered global generic pharmaceutical company developing and commercializing affordable solid oral dosage generics (tablets, capsules, suspensions) across the US, Europe, and Asia through subsidiaries in India, the US, and the UK.
- Company typePrivate
- Founded2015
- HeadquartersChennai, India
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eywa Pharma does
Eywa Pharma is a global generic pharmaceuticals company founded in April 2015 and headquartered in Singapore, with operating subsidiaries in India (Eywa Pharma Private Ltd, R&D in Chennai at Ticel Bio Park), the United States (Eywa Pharma Inc., commercial operations and historically manufacturing in Cranbury, New Jersey), and the United Kingdom/Europe (Zista Pharma Limited, commercial operations in Stevenage). The company develops and commercializes affordable generic medicines in solid oral dosage forms including tablets, capsules, oral suspensions, and solutions, with a differentiated portfolio strategy spanning niche products with limited or no generic competition, high-volume products, products going off-patent, and formulations addressing historical supply disruptions. The company also pursues strategic private label opportunities, including unit dose products.
The business operates a portfolio-based B2B distribution model, marketing products under the Eywa Label in the US and the Zista brand in the UK/Europe, with distribution through wholesalers, secondary distributors, and buying groups. As of December 2019, the company had filed 38 ANDAs and MAs with over 23 approvals, maintained a 70+ active product portfolio, and employed 100+ people globally. The company applies a Quality by Design framework across its development and manufacturing operations. In 2023, Eywa divested its Cranbury, New Jersey Oral Solid Dosage manufacturing facility to Biocon Generics Inc., which committed over USD 30 million to expand production capacity to 2 billion tablets annually. Post-divestiture, Eywa retains its commercial operations and R&D activities.
Eywa Pharma is backed by Eight Roads Ventures India (the proprietary investment arm of Fidelity International Limited), F-Prime Capital Partners, and Envestor Ventures Limited (part of the Shriram Group), with a USD 30 million funding round in October 2016 supporting formation and growth. Leadership includes co-founders Srinivasan Seshan and R. Jayakumar, both former senior executives at Matrix Laboratories and Mylan with 28-30 years of generics industry experience, supplemented by board members and investor representatives with deep operating, capital markets, and pharmaceutical expertise. The company is actively expanding geographic reach into China and other emerging markets through partnership-based distribution.
Eywa Pharma firmographics
Firmographics- Name
- Eywa Pharma
- Legal name
- Eywa Pharma Pte. Ltd.
- Website
- https://eywapharma.sg
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Eywa Pharma is a Singapore-headquartered global generic pharmaceutical company developing and commercializing affordable solid oral dosage generics (tablets, capsules, suspensions) across the US, Europe, and Asia through subsidiaries in India, the US, and the UK.
- Ownership category
- akta.pro rank
Eywa Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oral Solid Dose (OSD) Generics (HLAIABAD)
- akta.pro secondary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
Keywords
Where Eywa Pharma is headquartered
LocationHeadquarters
- HQ city
- Chennai
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Eywa Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales
Revenue model
- Generic Pharmaceutical Product Sales: Revenue generated through the sale of generic pharmaceutical products including tablets, capsules, oral suspensions and solutions. Products are sold under the Eywa Label in the US market and under the Zista brand in the UK market through distribution channels including wholesalers, secondary distributors, and buying groups. The company also pursues private label opportunities.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Eywa Pharma product offering
Product offeringCore offering
Eywa Pharma develops and manufactures generic pharmaceutical products in oral solid dosage forms, including tablets, capsules, oral suspensions, and solutions. The company operates a portfolio of 70+ active products, including niche products with limited or no generic competition, high-volume products, off-patent products, and products addressing historical supply disruptions, marketed under the Eywa Label in the US and under the Zista brand in the UK/Europe. Combination of in-house development at the Chennai facility and in-licensing supports portfolio expansion across multiple therapeutic areas.
Product overview
Eywa Pharma is a global generic pharmaceuticals company that develops and manufactures affordable, high-quality generic medicines. The company operates a portfolio-based business model with products spanning tablets, capsules, oral suspensions and solutions. The core product offering includes niche products with limited generic competition, high-volume products, products expected to go off-patent, and products addressing historical supply disruptions. Products are commercialized under the Eywa Label in the U.S. and under the Zista name in the UK, with strategic private label opportunities including unit dose arrangements. The company maintains development capabilities in Chennai, India and manufacturing capabilities in Cranbury, New Jersey, USA.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Pharmaceuticals Portfolio Portfolio of generic pharmaceutical products in oral solid dosage forms — tablets, capsules, oral suspensions, and solutions — covering niche products with limited or no generic competition, high-volume products, off-patent products, and products addressing historical supply disruptions across multiple therapeutic areas. Sold under the Eywa Label in the US and the Zista brand in the UK/Europe, with strategic private label opportunities including unit dose products.
Companies that use Eywa Pharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Eywa Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Eywa Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Global Development PartnerscoreStrategic partnerships with development partners globally for generic medicine development. The company has built strategic relationships for development, licensing opportunities, product acquisitions, and marketing partners for niche market segments.
- Licensing PartnerscoreStrategic in-licensing partners that contribute to Eywa's portfolio build-up. The company uses a combination of in-house development and strategic in-licensing to accelerate portfolio development, including 38+ ANDAs and MAs filed as of December 2019.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Eywa Pharma competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: India-headquartered global generic pharmaceutical company with a large US-focused oral solid dose portfolio and significant ANDA pipeline. Highly comparable to Eywa in business model (India R&D + US commercial) and target markets, but at materially greater scale.
- Dr. Reddy's Laboratories: Indian global generics company with strong US presence, broad oral solid dose portfolio, and active ANDA filing strategy. Shares Eywa's niche + complex generics positioning and India-to-US development-and-commercial model.
- Apotex: Large privately-held Canadian generic pharmaceutical company with a US and Canada commercial footprint and focus on affordable generic medicines. Comparable as a privately-held, multi-jurisdiction generic player pursuing similar limited-competition and difficult-to-make formulations.
- Lannett Company: US-focused generic drug manufacturer specializing in oral solid dose products with a portfolio of niche and limited-competition products. Closely comparable in scale, US-centric commercial model, and niche-generic positioning, including use of third-party manufacturing.
- Glenmark Pharmaceuticals: India-based global pharmaceutical company with a meaningful US generics business built on oral solid dose ANDAs and niche/specialty products. Comparable India-to-US development-and-commercial playbook and product mix.
- Zydus Cadila (Zydus Lifesciences): India-headquartered global generic and specialty pharma company with a strong US ANDA pipeline and broad oral solid dose portfolio. Comparable in geographic reach, dosage form focus, and India-to-US execution model.
- Strides Pharma Science: India-headquartered generic pharmaceutical company with a US-focused oral solid dose business, niche specialty generics, and India R&D plus US commercial operations. Closely matches Eywa's structural model, scale, and product mix.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a vast US ANDA portfolio spanning oral solids and other dosage forms. A broader incumbent whose pricing and capacity decisions shape the competitive dynamics Eywa competes within across all major distribution channels.
- Sandoz (Novartis): Global generic and biosimilar medicines business of Novartis with broad oral solid dose and complex generics portfolio. Sets the competitive baseline in regulated markets where Eywa commercializes and influences wholesaler purchasing decisions.
Others
- Biocon Limited: India-based biopharmaceutical company that acquired Eywa's Cranbury, NJ oral solid dose facility in 2023 and invested over $30M to scale it to 2 billion tablets annual capacity. Adjacent relationship as acquirer of Eywa's manufacturing asset and now an active competitor in US generic OSD supply.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Eywa Pharma social profiles
Digital presenceEywa Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eywa Pharma leadership team
Management profileNumber of profiles
Profiles7 records
Eywa Pharma subsidiaries and ownership
Company hierarchySubsidiaries3 records
Eywa Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eywa Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eywa Pharma
What does Eywa Pharma do?
Eywa Pharma develops and manufactures generic pharmaceutical products in oral solid dosage forms, including tablets, capsules, oral suspensions, and solutions. The company operates a portfolio of 70+ active products, including niche products with limited or no generic competition, high-volume products, off-patent products, and products addressing historical supply disruptions, marketed under the Eywa Label in the US and under the Zista brand in the UK/Europe. Combination of in-house development at the Chennai facility and in-licensing supports portfolio expansion across multiple therapeutic areas.
Is Eywa Pharma a public or private company?
Eywa Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eywa Pharma founded?
Eywa Pharma was founded in 2015. It employs 101 to 250 people.
Where is Eywa Pharma based?
Eywa Pharma is headquartered in Chennai, India, in the Asia region.
How does Eywa Pharma make money?
One revenue line is on record: generic Pharmaceutical Product Sales.
Who are Eywa Pharma's main competitors?
Direct peers on record are Aurobindo Pharma, Dr. Reddy's Laboratories, Apotex, Lannett Company, Glenmark Pharmaceuticals, Zydus Cadila (Zydus Lifesciences) and Strides Pharma Science. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis). Biocon Limited is listed as an others.
Does Eywa Pharma have an API?
No public API is recorded for Eywa Pharma.
What industry is Eywa Pharma in?
Eywa Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAD, Oral Solid Dose (OSD) Generics, with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.